Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome

免疫蛋白酶体缺乏是具有间充质表型的非小细胞肺癌的一个特征,并且与不良预后相关

阅读:5
作者:Satyendra C Tripathi, Haley L Peters, Ayumu Taguchi, Hiroyuki Katayama, Hong Wang, Amin Momin, Mohit Kumar Jolly, Muge Celiktas, Jaime Rodriguez-Canales, Hui Liu, Carmen Behrens, Ignacio I Wistuba, Eshel Ben-Jacob, Herbert Levine, Jeffrey J Molldrem, Samir M Hanash, Edwin J Ostrin

Abstract

The immunoproteasome plays a key role in generation of HLA peptides for T cell-mediated immunity. Integrative genomic and proteomic analysis of non-small cell lung carcinoma (NSCLC) cell lines revealed significantly reduced expression of immunoproteasome components and their regulators associated with epithelial to mesenchymal transition. Low expression of immunoproteasome subunits in early stage NSCLC patients was associated with recurrence and metastasis. Depleted repertoire of HLA class I-bound peptides in mesenchymal cells deficient in immunoproteasome components was restored with either IFNγ or 5-aza-2'-deoxycytidine (5-aza-dC) treatment. Our findings point to a mechanism of immune evasion of cells with a mesenchymal phenotype and suggest a strategy to overcome immune evasion through induction of the immunoproteasome to increase the cellular repertoire of HLA class I-bound peptides.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。